How to improve cancer care by use of guidelines and quality registers
DOI:
https://doi.org/10.2340/sju.v59.42272Abstract
N/A
Downloads
References
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265–273. https://doi.org/10.1080/21681805.2022.2094462 DOI: https://doi.org/10.1080/21681805.2022.2094462
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol. 2022;56(4):278–284. https://doi.org/10.1080/21681805.2022.2093396 DOI: https://doi.org/10.1080/21681805.2022.2093396
Liedberg F, Kjellström S, Lind AK, et al. Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma. Scand J Urol. 2022;56(2):137–146. https://doi.org/10.1080/21681805.2022.2041086 DOI: https://doi.org/10.1080/21681805.2022.2041086
Abuhasanein S, Jahnson S, Aljabery F, et al. Standardized care pathways for patients with suspected urinary bladder cancer: the Swedish experience. Scand J Urol. 2022;56(3):227–232. https://doi.org/10.1080/21681805.2022.2058605 DOI: https://doi.org/10.1080/21681805.2022.2058605
Scilipoti P, Liedberg F, Garmo H, et al. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population- based study. Scand J Urol. 2024;59:98–103. https://doi.org/10.2340/sju.v59.40001 DOI: https://doi.org/10.2340/sju.v59.40001
Åkerlund J, Sundqvist P, Ljungberg B, et al. Predictors for complication in renal cancer surgery: a national register study. Scand J Urol. 2023;58:38–45. https://doi.org/10.2340/sju.v58.12356 DOI: https://doi.org/10.2340/sju.v58.12356
Arnsrud Godtman R, Persson E, Bergengren O, et al. Surgeon volume and patient- reported urinary incontinence after radical prostatectomy. Population-based register study in Sweden. Scand J Urol. 2022;56(5–6):343–350. https://doi.org/10.1080/21681805.2022.2119270 DOI: https://doi.org/10.1080/21681805.2022.2119270
Gedeborg R, Sandin F, Thellenberg-Karlsson C, et al. Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden. Scand J Urol. 2023;58: 93-100 https://doi.org/10.2340/sju.v58.9572 DOI: https://doi.org/10.2340/sju.v58.9572
Bonde TM, Westerberg M, Aly M, et al. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non- metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scand J Urol. 2022;56(3):169–175. https://doi.org/10.1080/21681805.2022.2070275 DOI: https://doi.org/10.1080/21681805.2022.2070275
Gedeborg R, Lindhagen L, Loeb S, et al. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer. Scand J Urol. 2022;56(2):104–111. https://doi.org/10.1080/21681805.2021.2019304 DOI: https://doi.org/10.1080/21681805.2021.2019304
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pär Stattin MD, PhD

This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.


